Plain-English translation of NCT05849740 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether daratumumab, a type of antibody medication, works better when combined with corticosteroids to treat acquired hemophilia A—a condition where your body stops making enough blood-clotting proteins. About 25 people will participate across multiple hospitals in China. All participants will receive both the medication and steroids together to see if this combination can help control their bleeding.
Acquired hemophilia A is a serious bleeding disorder that can develop suddenly in adults, and current treatments don't always work well for everyone. Researchers hope this medication can offer patients a new, more effective option to manage their bleeding and reduce complications.
You likely qualify if…
You likely don't qualify if…
You will receive as part of this trial. The study involves visits to one of the participating hospitals in China, where you'll receive the medication and have your blood tested to monitor how well the treatment is working. The exact schedule of visits and treatment duration will be explained to you by the research team before you decide to participate.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~25 participants
Started
May 2023
Primary completion
April 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wei Liu
Chinese Academy of Medical Science and Blood Disease Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.